Ivan Samuel J, Holck Hailey W, Robinson Myra M, Shea Reilly E, Wallander Michelle L, Parker Blair, Matulay Justin T, Gaston Kris E, Clark Peter E, Seymour Rachel, Hsu Joseph R, Riggs Stephen B
Department of Urology, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Department of Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Urol Oncol. 2023 Oct;41(10):432.e1-432.e9. doi: 10.1016/j.urolonc.2023.05.022. Epub 2023 Jul 14.
Opioid use, misuse, and diversion is of paramount concern in the United States. Radical cystectomy is typically managed with some component of opioid pain control. We evaluated persistent opioid and benzodiazepine use after radical cystectomy and assessed the impact of their preoperative use on this outcome. We also explored associations between preoperative use and perioperative outcomes.
We used prospectively maintained data from our enhanced recovery after surgery (ERAS) cystectomy database and the Prescription Reporting with Immediate Medication Utilization Mapping (PRIMUM) database to identify controlled substance prescriptions for radical cystectomy patients. We separated patients by frequency of preoperative opioid and/or benzodiazepine prescriptions (0, 1, 2+) and used these cohorts to explore persistent use (prescription 3-12 months after surgery) alongside perioperative outcomes.
Our cohort included 257 patients undergoing cystectomy at a single institution from 2017 to 2021. Preoperative opioid and benzodiazepine prescriptions were documented for 120 (46.7%) and 26 (10.1%) patients, respectively. Persistent opioid use was observed in 20 (14.6%) of opioid-naive patients (no prescriptions in 9 months prior to surgery) while 13 (19.7%) patients with 1 preoperative prescription and 28 (51.9%) patients with 2 or more preoperative prescriptions demonstrated persistent use. New persistent benzodiazepine use occurred in 6 (2.6%) patients. Overall persistent benzodiazepine use was present in 11 (4.3%) patients. In a multivariable model, preoperative opioid and benzodiazepine prescriptions were associated with persistent opioid use (P < 0.001; P = 0.027 respectively). No association was identified between preoperative opioid or benzodiazepine usage and perioperative outcomes including length of stay, return of bowel function, inpatient opioid usage, inpatient or discharge complications, readmissions, or emergency department visits. Inpatient pain scores were noted to be higher in patients with ≥ 2 preoperative opioid prescriptions (P = 0.037).
Persistent opioid use was present in 23.7% of patients, with a new persistent use rate of 14.6%. Benzodiazepine use was less frequent than opioids, with a small number demonstrating new persistent use. Preoperative opioid and benzodiazepine use is associated with persistent opioid use postoperatively. Preoperative opioid and benzodiazepine use did not affect perioperative outcomes in our cohort.
在美国,阿片类药物的使用、滥用和转移是至关重要的问题。根治性膀胱切除术通常采用某种阿片类药物止痛措施进行管理。我们评估了根治性膀胱切除术后阿片类药物和苯二氮䓬类药物的持续使用情况,并评估了术前使用这些药物对这一结果的影响。我们还探讨了术前使用与围手术期结局之间的关联。
我们使用了来自我们的术后加速康复(ERAS)膀胱切除术数据库和即时药物利用映射处方报告(PRIMUM)数据库的前瞻性维护数据,以识别根治性膀胱切除术患者的管制药物处方。我们根据术前阿片类药物和/或苯二氮䓬类药物处方的频率(0、1、2+)对患者进行分组,并使用这些队列来探讨持续使用情况(术后3 - 12个月的处方)以及围手术期结局。
我们的队列包括2017年至2021年在单一机构接受膀胱切除术的257例患者。分别有120例(46.7%)和26例(10.1%)患者记录有术前阿片类药物和苯二氮䓬类药物处方。在术前未使用阿片类药物的患者(手术前9个月内无处方)中,有20例(14.6%)出现持续阿片类药物使用,而术前有1次处方的13例(19.7%)患者和术前有2次或更多次处方的28例(51.9%)患者出现持续使用。有6例(2.6%)患者出现新的苯二氮䓬类药物持续使用。总体而言,11例(4.3%)患者存在苯二氮䓬类药物持续使用。在多变量模型中,术前阿片类药物和苯二氮䓬类药物处方与持续阿片类药物使用相关(分别为P < 0.001;P = 0.027)。未发现术前阿片类药物或苯二氮䓬类药物使用与围手术期结局之间存在关联,包括住院时间、肠功能恢复、住院期间阿片类药物使用、住院或出院并发症、再入院或急诊科就诊。术前阿片类药物处方≥2次的患者住院疼痛评分更高(P = 0.037)。
23.7%的患者存在持续阿片类药物使用,新的持续使用率为14.6%。苯二氮䓬类药物的使用频率低于阿片类药物,少数患者出现新的持续使用。术前阿片类药物和苯二氮䓬类药物的使用与术后持续阿片类药物使用相关。在我们的队列中,术前阿片类药物和苯二氮䓬类药物的使用并未影响围手术期结局。